Clinical and Safety Outcomes with GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study.

Published in: The Journal of clinical endocrinology and metabolism (2022)

GLP-1RA and SGLT2i use in T1DM is associated with clinically relevant benefits. DKA remains a clinical concern with SGLT2i use, requiring careful patient selection and monitoring, with the risk to benefit ratio of treatment evaluated at an individual level.

Keyphrases

type diabetes
glycemic control
cardiovascular disease
case report
metabolic syndrome
adipose tissue
systemic lupus erythematosus
weight loss
smoking cessation